Galectin Therapeutics Inc. (GALT): Price and Financial Metrics
GALT Price/Volume Stats
| Current price | $3.37 | 52-week high | $4.27 |
| Prev. close | $3.38 | 52-week low | $1.28 |
| Day low | $3.20 | Volume | 206,132 |
| Day high | $3.47 | Avg. volume | 126,229 |
| 50-day MA | $2.43 | Dividend yield | N/A |
| 200-day MA | $1.95 | Market Cap | 208.62M |
GALT Stock Price Chart Interactive Chart >
Galectin Therapeutics Inc. (GALT) Company Bio
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company was founded in 2000 and is based in Norcross, Georgia.
Latest GALT News From Around the Web
Below are the latest news stories about GALECTIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GALT as an investment opportunity.
Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023Company Faces Higher R&D Expenses Amid Progress in Clinical Programs |
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President |
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President |
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDPharmacokinetics and safety of belapectin in patients with hepatic insufficiencyLack of impact of belapectin on cardiac repolarization (QT interval)Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progression in patient with portal hypertension and liver cirrhosisClinical significance and interpretation of serum galectin-3 levels in patients with advanced liver diseaseImpact of obesity and muscle wasting to evaluate renal function in patients with portal hype |
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Tuesday, October 24, 2023 at 11:30 AM ET. A live webcast of the discussion will be |
GALT Price Returns
| 1-mo | 53.18% |
| 3-mo | 92.57% |
| 6-mo | 65.20% |
| 1-year | 70.20% |
| 3-year | 24.81% |
| 5-year | -21.63% |
| YTD | 103.01% |
| 2023 | 46.90% |
| 2022 | -45.41% |
| 2021 | -7.59% |
| 2020 | -21.68% |
| 2019 | -16.62% |
Loading social stream, please wait...